Guidance worksheet, issued 5/9/16

Assumes Cleviprex, Kengreal, and Argatroban sold as of 7/1/16

	GAAP Guidance	Adjusted Guidance	Commentary
Net Revenue	$160 - $170mn	$160 - $170mn	Includes The Medicines Company's share of royalty revenue from the net profit (as defined) on sales of authorized generic Angiomax by Sandoz, as well as net revenues on sales of our other marketed products
Cost of Revenue	36 - 46%	20 - 30%	GAAP number includes ~$26mn of intangible amortization
R&D	$138 - $148mn	$128 - $138mn	GAAP number includes ~$10mn of milestone payments, severance and stock based compensation
SG&A	$308 - $318mn	$247 - $257mn	GAAP number includes ~$61mn of changes in contingent consideration, severance and stock based compensation
Tax Benefit	no tax benefit from loss; minimal cash taxes	no tax benefit from loss; minimal cash taxes	

Statements contained in this guidance worksheet about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "estimates", "expects", "assumes"and similar expressions, including the Company's financial guidance estimated for 2016, are intended to identify forward-looking statements. These forward-looking statements involve important known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of our products; the Company's ability to develop its global operations and penetrate foreign markets; whether the Company is able to raise additional capital on favorable terms or at all; whether the Company's product candidates will advance in the clinical trials process on a timely basis or at all; whether the Company will make regulatory submissions for product candidates on a timely basis; whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis or at all; whether the Company's ongoing and planned commercial launches will be successful; whether physicians, patients and other key decision makers will accept clinical trial results; whether the Company can protect its intellectual property; the ability of the Company and Chiesi to consummate the cardiovascular product transaction announced today; satisfaction of the conditions to the completion of the cardiovascular product transaction, including, without limitation, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; the commercial success of such cardiovascular products and the achievement of future milestone payments; and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's annual report on Form 10-K filed with the SEC on February 29, 2016, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.

In addition to the financial guidance estimates presented in accordance with U.S. GAAP, this guidance worksheet also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted measures reflect the exclusions referenced in the footnotes to the table, are non-GAAP and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways.